No Picture
News

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX. The presentations demonstrate the suboptimal outcomes associated… Click here to view original post… […]

No Picture
News

Shoreline Biosciences Announces $140M Financing To Advance Pipeline Of Next Generation Cell Immunotherapies

SAN DIEGO: SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized, and targeted induced pluripotent stem cells (iPSC) derived natural killer (NK) and macrophage cellular immunotherapies, today announced the completion of a $140M financing, led by Ally Bridge Group,… Click here to view original post… […]

No Picture
News

CalciMedica Strengthens Board of Directors with Appointment of Finance Veteran Allan L. Shaw

LA JOLLA, Calif.: LA JOLLA, Calif., Nov. 2, 2021 /PRNewswire/ — CalciMedica Inc. ("CalciMedica" or the "Company), the CRAC channel company, today announced the appointment of Allan L. Shaw to its Board of Directors. "We welcome Allan to our team and are excited to draw on his impressive background in… Click here to view original post… […]

No Picture
News

BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies

SAN DIEGO: SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines, today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with a Phase 1 clinical trial of BTX-1188 in hematologic and solid… Click here to view original post… […]

No Picture
News

OncoSec Medical Hosting SITC Key Opinion Leader Webinar on Updated Data from the KEYNOTE-695 Study

PENNINGTON, N.J. and SAN DIEGO: PENNINGTON, N.J. and SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) will host a conference call and webcast for investors and analysts on Friday, November 12 at 7:00 AM ET featuring key opinion leaders (KOLs) Matteo Carlino, MD, from Westmead and… Click here to view original post… […]

No Picture
News

HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF PHASE 2 ATRIAL FIBRILLATION TRIAL

SAN DIEGO: SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that the first patient has been dosed in a Phase 2 study of HUYABIO’s novel drug for cardioversion of atrial fibrillation (AF) at Wellington Regional Hospital… Click here to view original post… […]

No Picture
News

Fresh off Kite and BeiGene deals, Shoreline ups the ante with a hefty crossover. But the biotech insists it’s in no rush

Though it may seem like Shoreline Biosciences is rapidly gaining momentum with a flurry of deals — and, now, a new funding round — Kleanthis Xanthopoulos doesn’t feel he’s in a rush. The biotech’s chief executive put the bow on a $140 million Series B on Tuesday, as Shoreline… Click here to view original post… […]

No Picture
News

Sorrento’s License Partner, Lee’s Pharmaceutical Announces NDA Filing Acceptance by NMPA for Anti-PD-L1 Antibody Socazolimab for Treatment of Recurrent or Metastatic Cervical Cancer

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that its license partner, China Oncology Focus Limited (COF), an affiliate of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma, HKEX: 950) has submitted a NDA (new drug application) for the anti-PD-L1 antibody, socazolimab, licensed… Click here to view original post… […]

No Picture
News

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted an inducement award to one new employee, Mohab Hassanin, who joined the Company as Clinical Trial Manager. Click here to view original post… […]

No Picture
News

eFFECTOR Appoints Barbara Klencke, M.D., to Board of Directors

SAN DIEGO, Nov. 01, 2021 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced the appointment of Barbara Klencke, M.D., Chief Medical Officer and Chief Development Officer at Sierra Oncology, to the company’s… Click here to view original post… […]

No Picture
News

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

SAN DIEGO: SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — Inhibrx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced today that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November… Click here to view original post… […]

No Picture
News

Neurocrine Biosciences Reports Third Quarter 2021 Financial Results

SAN DIEGO: SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. "Our third quarter results reflect INGREZZA’s continued growth. With this momentum and increased investment to expand our commercial footprint, we can better serve… Click here to view original post… […]

No Picture
News

Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021

SAN DIEGO: SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent corporate updates on Monday, November 8. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on… Click here to view original post… […]

No Picture
News

Acadia Pharmaceuticals Appoints Brendan Teehan, Executive Vice President, Chief Operating Officer, Head of Commercial

SAN DIEGO–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Brendan Teehan to Executive Vice President, Chief Operating Officer, Head of Commercial, effective immediately. Mr. Teehan, previously Senior Vice President, Chief Insights and Analytics Officer, will continue to report to Steve Davis, Chief Executive Officer and continue to… Click here to view original post… […]

No Picture
News

Cue Health Provides Molecular COVID-19 Testing To MLB Clubs During The Postseason And World Series

NEW YORK and SAN DIEGO: NEW YORK and SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, and Major League Baseball (MLB) today announced that Cue has been providing all Clubs, as well as the league office, with its integrated Cue platform,… Click here to view original post… […]

No Picture
News

Neurocrine Biosciences Presents New INGREZZA® (valbenazine) Data at Psych Congress 2021

SAN DIEGO: SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it presented new data from its movement disorder program for tardive dyskinesia (TD) at the 2021 Psych Congress scientific meeting being held October 29–November 1, 2021. Key highlights include: New pooled analysis from… Click here to view original post… […]

No Picture
News

NuVasive to Present at Credit Suisse 30th Annual Healthcare Conference

SAN DIEGO: SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will virtually present at the Credit Suisse 30th Annual Healthcare Conference on Thursday, November 11, 2021… Click here to view original post… […]

No Picture
News

Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021

SAN DIEGO: SAN DIEGO, Nov. 1, 2021 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the glucagon-like peptide-1… Click here to view original post… […]